Trials find no benefits of Zetia

Jan 15, 2008

The U.S. makers of the cholesterol-lowering drug Zetia say a clinical trial failed to identify any medical benefits of the medication.

Merck and Schering-Plough, the New Jersey companies that jointly market Zetia and Vytorin, a drug that combines Zetia with the cholesterol drug Zocor, said that while Zetia has been shown to reduce cholesterol by 15 percent to 20 percent in most patients, it was not found to reduce the risk of heart attacks or strokes, The New York Times reported Monday.

The trial also found no evidence the drug reduces the growth of fatty plaque in arteries. The trial had been designed to show the drug could fight growth of plaque.

Dr. Steven Nissen, chairman of cardiology at the Cleveland Clinic, called the results "shocking" and said patients should not take Zetia unless all other cholesterol drugs have been tried and failed.

"This is as bad a result for the drug as anybody could have feared," he said.

Copyright 2008 by United Press International

Explore further: Drug prices to treat multiple sclerosis soar, point to larger problem

Related Stories

Merck 2Q profit more than doubles

Jul 29, 2014

A big one-time gain and a tax benefit helped drugmaker Merck & Co. more than double its second-quarter profit, raise the lower end of its profit forecast and easily top analysts' expectations.

Cholesterol: The good, the bad, the unknown

Feb 21, 2011

Two people are diagnosed with high cholesterol, one of the leading risk factors for heart disease, and follow similar therapies. One ends up with improved cholesterol levels, but the other doesn't.

Study raises new questions about Merck pill Zetia

Nov 16, 2009

(AP) -- A new study raises fresh concerns about Zetia and its cousin, Vytorin - drugs still taken by millions of Americans to lower cholesterol, despite questions raised last year about how well they work.

FDA won't accept Merck's application for new drug

Nov 02, 2009

(AP) -- U.S. regulators have refused to accept drugmaker Merck & Co.'s application for a new, combination cholesterol pill that includes rival Pfizer's Lipitor, the world's top-selling drug.

Recommended for you

Rising antibiotic shortages raise concerns about patient care

Apr 23, 2015

Shortages of key antibiotics, including gold-standard therapies and drugs used to treat highly resistant infections, are on the rise, according to a new study of shortages from 2001 to 2013 published in Clinical Infectious Di ...

Study supports HPV vaccination guidelines

Apr 21, 2015

(HealthDay)—New research finds that young women who get the HPV vaccine gain significant protection against infection in three parts of the body if they haven't already been exposed to the human papillomavirus.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.